Effects of AM1346, a high-affinity CB1 receptor selective anandamide analog, on open-field behavior in rats

Behavioural Pharmacology

Volumn 18, Issue 7, 2007, Pages 673-680

  Järbe, Torbjörn U C ^a,d   DiPatrizio, Nicholas V ^a,b   Li, Chen ^c   Makriyannis, Alexandros ^d  

^a TEMPLE UNIVERSITY   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF CONNECTICUT   (United States)

^d NORTHEASTERN UNIVERSITY   (United States)

Author keywords

AM1346; Anandamide analog; Open field; Rat; SR141716

Indexed keywords

ANANDAMIDE DERIVATIVE; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; METHANANDAMIDE; RIMONABANT; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DEFECATION; DOSE RESPONSE; GROOMING; MALE; MOBILIZATION; NONHUMAN; OPEN FIELD BEHAVIOR; RAT; REARING; SCRATCHING; VOCALIZATION;

ANIMALS; ARACHIDONIC ACIDS; BEHAVIOR, ANIMAL; DEFECATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INVERSE AGONISM; EXPLORATORY BEHAVIOR; GROOMING; MALE; MOTOR ACTIVITY; PIPERIDINES; POLYUNSATURATED ALKAMIDES; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; STEREOTYPED BEHAVIOR; TETRAHYDROCANNABINOL; VOCALIZATION, ANIMAL;

EID: 34948822297     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/FBP.0b013e3282f00bbf     Document Type: Article

References (46)

1. Abadji V, Lin S, Taha G, Griffin G, Stevenson LA, Pertwee RG, Makriyannis A (1994). (R)-Methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J Med Chem 37:1889-1893.
2. Adams IB, Compton DR, Martin BR (1998). Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain. J Pharmacol Exp Ther 284:1209-1217.
3. 9-tetrahydrocannabinol and methanandamide in CB1 knockout and wild-type mice. J Pharmacol Exp Ther 309:86-91.
4. Bonhaus DW, Chang LK, Kwan J, Martin GR (1998). Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist-specific trafficking of intracellular responses. J Pharmacol Exp Ther 287:884-888.
5. 9-tetrahydrocannabinol. J Pharmacol Exp Ther 285:1150-1156.
6. Coutts AA, Izzo AA (2004). The gastrointestinal pharmacology of cannabinoids: an update. Curr Opin Pharmacol 4:572-579.
7. 2A receptor-mediated behaviors in mice. Pharmacol Biochem Behav 68:311-317.
8. 1 receptor antagonist SR 141716A in naïve mice. J Neural Transm 107:931-945.
9. 1 receptor antagonist SR 141716A increase brain serotonin and dopamine levels and turnover. Pharmacol Biochem Behav 75:777-787.
10. Eilam D, Talangbayan H, Canaran G, Szechtman H (1992). Dopaminergic control of locomotion, mouthing, snout contact, and grooming: opposing roles of D1 and D2 receptors. Psychopharmacology (Berl) 106:447-454.
11. Ferrari F, Ottani A, Giuliani D (1999). Cannabinoid activity in rats and pigeons of HU 210, a potent anti-emetic drug. Pharmacol Biochem Behav 62:75-80.
12. 9-tetrahydrocannabinol. Brain Res 697:83-90.
13. Fride E, Feigin C, Ponde DE, Breuer A, Hanus L, Arshavsky N, Mechoulam R (2004). (+)-Cannabidiol analogues which bind cannabinoid receptors but exert peripheral activity only. Eur J Pharmacol 506:179-188.
14. Giuliani D, Ferrari F, Ottani A (2000). The cannabinoid agonist HU 210 modifies rat behavioural responses to novelty and stress. Pharmacol Res 41:47-53.
15. Henriksson BG, Järbe T (1971). Cannabis-induced vocalization in the rat. J Pharm Pharmacol 23:457-458.
16. Hiltunen AJ, Järbe TUC, Wängdahl K (1988). Cannabinol and cannabidiol in combination: temperature, open-field activity, and vocalization. Pharmacol Biochem Behav 30:675-678.
17. 9-THC and other cannabinoids. Pharmacol Biochem Behav 71:155-162.
18. Järbe TUC, Henriksson BG (1973). Vocalization: a characteristic cannabis-induced behavior in the rat? Physiol Psychol 1:351-354.
19. Järbe TUC, Hiltunen AJ (1987). Cannabimimetic activity of cannabinol in rats and pigeons. Neuropharmacology 26:219-228.
20. 9-THC and (R)-methanandamide on open-field behaviors in rats. Behav Pharmacol 9:169-174.
21. 9-THC training dose as a determinant for (R)-methanandamide generalization in rats. Psychopharmacology (Berl) 140:519-522.
22. 9-THC training dose as a determinant for (R)-methanandamide generalization in rats: a systematic replication. Behav Pharmacol 11:81-86.
23. 9-THC as discriminative stimuli in rats: tests with the cannabinoid antagonist SR-141716 and the endogenous ligand anandamide. Psychopharmacology (Berl) 156:369-380.
24. 1 receptor antagonist SR-141716 in rats: open-field revisited. Pharmacol Biochem Behav 73:911-919.
25. Järbe TUC, DiPatrizio NV, Li C, Makriyannis A (2003a). The cannabinoid receptor antagonist SR-141716 does not readily antagonize open-field effects induced by the cannabinoid receptor agonist (R)-methanandamide in rats. Pharmacol Biochem Behav 75:809-821.
26. 9-THC induced operant rate decreases in rats are not readily antagonized by SR-141716A. Eur J Pharmacol 466:121-127.
27. 8-tetrahydrocannabinol (AM-411), a selective cannabinoid CB1 receptor agonist: effects on open-field behaviors and antagonism by SR-141716 in rats. Behav Pharmacol 15:517-521.
28. 9-THC or (R)-methanandamide. Psychopharmacology (Berl) 188:315-323.
29. Järbe TUC, Ross T, DiPatrizio NV, Pandarinathan L, Makriyannis A (2006b). Effects of the CB1R agonist WIN-55 212-2 and the CB1R antagonists SR-141716 and AM-1387: open-field examination in rats. Pharmacol Biochem Behav 85:243-252.
30. Jones MP, Wessinger S (2005). Small intestinal motility. Curr Opin Gastroenterol 21:141-146.
31. Landi M, Croci T, Rinaldi-Carmona M, Maffrand JP, Le Fur G, Manara L (2002). Modulation of gastric emptying and gastrointestinal transit in rats through intestinal cannabinoid CB(1) receptors. Eur J Pharmacol 450:77-83.
32. 9- tetrahydrocannabinol and morphine-dependent mice. J Pharmacol Exp Ther 298:1007-1014.
33. Makriyannis A, Goutopoulos A. (2004). Cannabinergics: old and new therapeutic possibilities. In: Makriyannis A, Biegel D, editors. Drug discovery strategies and methods 1. New York: Marcel Dekker Inc.; pp. 89-128.
34. Mukhopadhyay S, Howlett AC (2005). Chemically distinct ligands promote differential CB1 cannabinoid receptor-Gi protein interactions. Mol Pharmacol 67:2016-2024.
35. Navarro M, Hernandez E, Munoz RM, del Arco I, Villanua MA, Carrera MR, Rodriguez de Fonseca F (1997). Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. NeuroReport 8:491-496.
36. National Institutes of Health (1996). Principles of animal laboratory care. Washington, DC: National Academy Press.
37. Picone RP, Khanolkar AD, Xu W, Ayotte LA, Thakur GA, Hurst DP, et al. (2005). (-)-7′-Isothiocyanato-11-hydroxy-1′,1′- dimethylheptylhexahydrocannabinol (AM841), a high-affinity electrophilic ligand, interacts covalently with a cysteine in helix six and activates the CB1 cannabinoid receptor. Mol Pharmacol 68:1623-1635.
38. Rubino T, Patrini G, Massi P, Fuzio D, Vigano D, Giagnoni G, Parolaro D (1998). Cannabinoid-precipitated withdrawal: a time-course study of the behavioral aspect and its correlation with cannabinoid receptors and G protein expression. J Pharmacol Exp Ther 285:813-819.
39. Rubino T, Vigano D, Zagato E, Sala M, Parolaro D (2000). In vivo characterization of the specific cannabinoid receptor antagonist, SR141716A: behavioral and cellular responses after acute and chronic treatments. Synapse 35: 8-14.
40. Schlicker E, Kathman M (2001). Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci 22:565-572.
41. Shoemaker JL, Ruckle MB, Mayeux PR, Prather PL (2005). Agonist-directed trafficking of response by endocannabinoids acting at CB2 receptors. J Pharmacol Exp Ther 315:828-838.
42. Sjödén P-O, Järbe TUC, Henriksson BG (1973). Effects of long-term administration and withdrawal of tetrahydrocannabinols (delta-8-THC and delta-9-THC) on open-field behavior in rats. Pharmacol Biochem Behav 1: 243-249.
43. Thakur GA, Nikas SP, Li C, Makriyannis A. (2005.) Structural requirements for cannabinoid receptor probes. In: Pertwee R, editor. Handbook of experimental pharmacology. Vol 168. New York: Springer; pp. 209-246.
44. Vickers SP, Webster LJ, Wyatt A, Dourish CT, Kennett GA (2003). Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Psychopharmacology (Berl) 167:103-111.
45. Viveros MP, Marco EM, File SD (2005). Endocannabinoid system and stress and anxiety responses. Pharmacol Biochem Behav 81:331-342.
46. Weissman A, Milne GM, Melvin LS Jr (1982). Cannabimimetic activity from CP-47,497, a derivative of 3-phenylcyclohexanol. J Pharmacol Exp Ther 223:516-523.